Law Office Of Brodsky & Smith, LLC Announces Investigation Of Medicis Pharmaceutical Corporation

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE-MRX) relating to the proposed acquisition by Valeant Pharmaceutical. (“Valeant”).

Under the terms of the transaction, Medicis shareholders will receive only $44.00 in cash for each share of Medicis stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medicis for not acting in the Company’s shareholders' best interests in connection with the sale process to Valeant. The transaction may undervalue the Company as an analyst has set a price target for Medicis stock at $45.00 per share.

If you own shares of Medicis stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/471-mrx-medicis-pharmaceutical-corporation.html, or by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010

If you liked this article you might like

Apple Turns 40 With Little Fanfare as March to Dow 20K Resumes: ICYMI

Apple Turns 40 With Little Fanfare as March to Dow 20K Resumes: ICYMI

Medicis Stock Hits New 52-Week High (MRX)

Medicis Stock Hits New 52-Week High (MRX)

Medicis Pharmaceuticals Corporation (MRX): Today's Featured Drugs Laggard

Medicis Pharmaceuticals Corporation (MRX): Today's Featured Drugs Laggard

Medicis Stock To Go Ex-dividend Tomorrow (MRX)

Medicis Stock To Go Ex-dividend Tomorrow (MRX)

Cramer's 'Mad Money' Recap: The Worse It Gets, the Better

Cramer's 'Mad Money' Recap: The Worse It Gets, the Better